八氢-1-二并环戊烯并l | 94247-94-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 八氢-1-二并环戊烯并l
• 英文名称: bicyclo[3.3.0]octan-2-ol
• 英文别名: 2-Hydroxybicyclo<3.3.0>octan；2-Hydroxybicyclo[3.3.0]octan；Octahydropentalenol；1,2,3,3a,4,5,6,6a-octahydropentalen-1-ol
• CAS: 94247-94-6
• 化学式: C₈H₁₄O
• 分子量: 126.199
• InChiKey: AOONMBCPMGBOBG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  八氢-1-二并环戊烯并l 在 pyridinium chlorochromate 作用下， 生成 Semicarbazon des cis-Bicyclo<0.3.3>octanons-(2)
  参考文献：
  名称：

  吸附在硅胶上的高氯酸铁 (III)：有机官能团转化的试剂

  摘要：

  摘要 在有机溶剂（S=水、乙腈或低级脂肪酸）存在下，将 Fe(ClO4)3(H2O)6 吸附到色谱级硅胶上会产生一种负载型试剂 Fe(ClO4)3(S)6 /SiO2。已发现该试剂可有效进行快速有机官能团转化，例如炔烃、芳烃的二聚化、硫醇选择性氧化为二硫化物，以及使用杵和研钵在固态研磨时 1,5-环辛二烯中的跨环反应.

  DOI：

  10.1080/00397910701410772
• 作为产物：
  描述：

  氧化环辛烯 在 碘 、 氢气 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 反应 29.17h， 生成 八氢-1-二并环戊烯并l
  参考文献：
  名称：

  碘代三甲基硅烷和DBU将环氧乙烷逐步转化为烯丙醇

  摘要：

  由六甲基乙硅烷和碘制得的碘三甲基硅烷与环氧乙烷平稳反应，生成（2-碘烷氧基）三甲基硅烷，可以用DBU以高收率将其转化为烯丙基醇。整个转换可以一锅进行。

  DOI：

  10.1016/s0040-4039(00)92598-x

文献信息

• [EN] NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES AZOTÉS ET LEUR APPLICATION DANS DES MÉDICAMENTS
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2014012360A1

  公开（公告）日：2014-01-23

  The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

  本发明涉及医学领域，提供了新型含氮杂环化合物，其制备方法及其作为药物的用途，特别是用于治疗和预防组织纤维化。还提供了含有这些含氮杂环化合物的药用可接受的组合物，以及这些组合物在治疗人类或动物组织纤维化方面的用途，特别是用于人类或动物肾间质纤维化、肾小球硬化、肝纤维化、肺纤维化、腹膜纤维化、心肌纤维化、皮肤纤维化、术后粘连、良性前列腺增生、骨骼肌纤维化、硬皮病、多发性硬化、胰腺纤维化、肝硬化、肌肉瘤、神经纤维瘤、肺间质纤维化、糖尿病肾病、阿尔茨海默病或血管纤维化。
• Nitrogenous Heterocyclic Derivatives And Their Application In Drugs
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US20150087639A1

  公开（公告）日：2015-03-26

  The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

  本发明涉及医学领域，提供了新颖的含氮杂环化合物，其制备方法及其作为药物的用途，特别是用于治疗和预防组织纤维化。还提供了包含这些含氮杂环化合物的药用组合物，以及这些组合物在治疗人类或动物组织纤维化方面的用途，特别是用于人类或动物肾间质纤维化、肾小球硬化、肝纤维化、肺纤维化、腹膜纤维化、心肌纤维化、皮肤纤维化、术后粘连、良性前列腺增生、骨骼肌纤维化、硬皮病、多发性硬化、胰腺纤维化、肝硬化、肌肉肉瘤、神经纤维瘤、肺间质纤维化、糖尿病肾病、阿尔茨海默病或血管纤维化。
• Microwave-Assisted Isomerizations of Epoxides to Allylic Alcohols
  作者：Gabriella Barozzino-Consiglio、Alessandro Mordini

  DOI：10.2174/1570178615666180215145359

  日期：2018.4.12

  The present work reports a study on the isomerization reactions of several alkyl epoxides to the corresponding allylic alcohols or bicyclic alcohols under microwave irradiation. The reaction occurred in the presence of lithium diisopropylamide as a base and different experimental conditions in terms of solvent, amount of the base, times and temperatures. The traditional heating with an oil-bath and

  本工作报告了在微波辐射下几种烷基环氧化物与相应的烯丙基醇或双环醇的异构化反应的研究。该反应在二异丙基氨基化锂作为碱的存在下以及在溶剂，碱的量，时间和温度方面的不同实验条件下发生。与微波加热相比，使用油浴的传统加热以及使用替代的有机金属碱（如Lochmann-Schlosser碱）已得到进一步的发展。获得的结果表明，使用微波辐射促进环氧化物的异构化可以得到一系列合成上有用的产品，其中取决于起始底物，其中烯丙基醇和双环醇。
• Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B / 2C adrenergic receptors
  申请人：Allergan Sales, Inc.

  公开号：US20020156076A1

  公开（公告）日：2002-10-24

  Compounds having adrenergic activity which are a selective agonists for one or both of the &agr; 2B and &agr; 2c adrenoceptor receptor subtypes in preference to the &agr; 2A adrenoceptor receptor subtype; the active compound being selected from the group consisting of compounds having the formula 1 wherein the dotted lines represent optional bonds provided that two double bonds may not share a common carbon atom; R is H or lower alkyl; X is S or C(H)R 1 , wherein R 1 is H or lower alkyl, but R 1 is absent when the bond between X and the ring represented by 2 is a double bond; Y is O, N, S, (CR 1 2 ) y , wherein y is an integer of from 1 to 3, —CH═CH— or —Y 1 CH 2 —, wherein Y 1 is O, N or S; x is an integer of 1 or 2, wherein x is 1 when R 2 , R 3 or R 4 is bound to an unsaturated carbon atom and x is 2 when R 2 , R 3 or R 4 is bonded to a saturated carbon atom; R 2 is H, lower alkyl, halogen, hydroxy, lower alkoxy, lower alkenyl, acyl or lower alkynyl, or, when attached to a saturated carbon atom, R 2 may be oxo; R 3 and R 4 are, each, H, lower alkyl, halogen, lower alkenyl, acyl, lower alkynyl, aryl, heteroaryl, or sub stituted aryl or heteroaryl, wherein said substituent is halogen, lower alkyl, lower alkoxy, lower alkenyl, acyl, lower alkynyl, nitro, cyano, trifluoromethyl, hydroxy, or phenyl or, together, are —(C(R 2 )x)z—; —Y 1 (C(R 2 )x)z′—; —Y 1 (C(R 2 )x)y Y 1 —; —(C(R 2 )x)—Y 1 —(C(R 2 )x)—; —(C(R 2 )x)—Y 1 —(C(R 2 )x)—(C(R 2 )x)— and —Y 1 —(C(R 2 )x)—Y 1 —(C(R 2 )x)— wherein z is an integer of from 3 to 5, z′ is an integer of from 2 to 4 and x and y are as defined above, and further either end of each of these divalent moieties may attach at either R3 or R4 to form a condensed ring structure and the rings formed may be totally unsaturated, partially unsaturated, or totally saturated; and being useful for treating muscle spasticity including hyperactive micturition, diarrhea, diuresis, withdrawal syndromes, pain including neuropathic pain, neurodegenerative diseases, memory and cognition deficits, psychoses including manic disorders and anxiety, hypertension, cardiac ischemia, congestive heart failure, and nasal congestion without sedating or cardiovascular side effects.

  具有肾上腺素活性的化合物，是选择性激动剂，优先作用于α2B和α2C肾上腺素受体亚型中的一个或两个，而不是α2A肾上腺素受体亚型；所述活性化合物从以下化合物组中选择，其具有下列式1的化合物，其中虚线代表可选键，但两个双键不能共用一个碳原子；R为H或较低的烷基；X为S或C(H)R1，其中R1为H或较低的烷基，但当X与由2表示的环之间的键为双键时，R1不存在；Y为O、N、S、(CR12)y，其中y为1至3的整数，—CH2CH—或—Y1CH2—，其中Y1为O、N或S；x为1或2的整数，当R2、R3或R4与不饱和碳原子结合时，x为1，当R2、R3或R4与饱和碳原子结合时，x为2；R2为H、较低的烷基、卤素、羟基、较低的烷氧基、较低的烯基、酰基或较低的炔基，或者当连接到饱和碳原子时，R2可能为酮基；R3和R4分别为H、较低的烷基、卤素、较低的烯基、酰基、较低的炔基、芳基、杂环芳基或取代的芳基或杂环芳基，其中所述取代基为卤素、较低的烷基、较低的烷氧基、较低的烯基、酰基、较低的炔基、硝基、氰基、三氟甲基、羟基或苯基，或者共同为—(C(R2)x)z—；—Y1(C(R2)x)z′—；—Y1(C(R2)x)y Y1—；—(C(R2)x)—Y1—(C(R2)x)—；—(C(R2)x)—Y1—(C(R2)x)—(C(R2)x)—和—Y1—(C(R2)x)—Y1—(C(R2)x)—其中z为3至5的整数，z′为2至4的整数，x和y如上所定义，而且这些二价基团的每一端都可以连接到R3或R4中的任一端，形成一个紧凑的环结构，所形成的环可以是完全不饱和的、部分不饱和的或完全饱和的；并且适用于治疗肌肉痉挛，包括过度活跃的小便、腹泻、利尿、戒断综合征、包括神经病理性疼痛、神经退行性疾病、记忆和认知缺陷、精神病，包括躁狂障碍和焦虑、高血压、心肌缺血、充血性心力衰竭和鼻塞，无镇静或心血管副作用。
• Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
  申请人：ALLERGAN SALES, INC.

  公开号：US20030023098A1

  公开（公告）日：2003-01-30

  Methods and compounds for the treatment of conditions including pain, particularly chronic pain, glaucoma or elevated intraocular pressure with reduced cardiovascular or sedative side effects. Also included are methods of making and using such compounds.

  用于治疗疼痛、特别是慢性疼痛、青光眼或高眼压的方法和化合物，具有减少心血管或镇静副作用。还包括制备和使用这些化合物的方法。